• Interaction Score: 2.36

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Approval Status Preclinical
    Indication/Tumor Type non-small cell lung carcinoma
    combination therapy Emibetuzumab + Erlotinib


    Sources:
    JAX-CKB TTD